BioNTech fund pays €600m to early backers after vaccine success
MIG has provided funding to the German biotech company, which developed the vaccine with US drugmaker Pfizer, since 2008
04 February 2021 - 18:13
Frankfurt — German venture capital firm MIG, which was among the first backers of Covid-19 vaccine developer BioNTech, has paid €600m to its investors, cashing out parts of an initial investment of €13.5m.
MIG said on Thursday that investors in its funds would now receive €340m from the sale of an unspecified stake in BioNTech, following a payout of €260m in 2020...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.